[Federal Register: February 20, 2009 (Volume 74, Number 33)]
[Notices]
[Page 7925]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr20fe09-94]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated October 9, 2008 and published in the Federal
Register on October 17, 2008, (73 FR 61911), Noramco Inc., 1440 Olympic
Drive, Athens, Georgia 30601, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053)...................... I
Morphine-N-oxide (9307)..................... I
Amphetamine (1100).......................... II
Methylphenidate (1724)...................... II
Codeine (9050).............................. II
Dihydrocodeine (9120)....................... II
Oxycodone (9143)............................ II
Hydromorphone (9150)........................ II
Hydrocodone (9193).......................... II
Morphine (9300)............................. II
Oripavine (9330)............................ II
Thebaine (9333)............................. II
Oxymorphone (9652).......................... II
Alfentanil (9737)........................... II
Sufentanil (9740)........................... II
Carfentanil (9743).......................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the schedule I
controlled substances for internal testing; the schedule II controlled
substances will be manufactured in bulk for distribution to its
customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Noramco Inc. to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time. DEA has
investigated Noramco Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above
named company is granted registration as a bulk manufacturer of the
basic classes of controlled substances listed.
Dated: February 13, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-3649 Filed 2-19-09; 8:45 am]
BILLING CODE 4410-09-P